AstraZeneca (AZNS) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
AZNS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1,504.50 |
| 52 Week High | UK£1,922.50 |
| 52 Week Low | UK£1,389.00 |
| Beta | 0.21 |
| 1 Month Change | -18.87% |
| 3 Month Change | -12.49% |
| 1 Year Change | 2.21% |
| 3 Year Change | 5.65% |
| 5 Year Change | 52.82% |
| Change since IPO | 408.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| AZNS | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -10.2% | -7.9% | 0.4% |
| 1Y | 2.2% | 10.4% | 18.8% |
Return vs Industry: AZNS underperformed the UK Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: AZNS underperformed the UK Market which returned 18.4% over the past year.
Price Volatility
| AZNS volatility | |
|---|---|
| AZNS Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: AZNS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: AZNS's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 96,100 | Pascal Claude Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
AstraZeneca PLC Fundamentals Summary
| AZNS fundamental statistics | |
|---|---|
| Market cap | SEK 2.33t |
| Earnings (TTM) | SEK 99.48b |
| Revenue (TTM) | SEK 584.42b |
Is AZNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZNS income statement (TTM) | |
|---|---|
| Revenue | US$61.37b |
| Cost of Revenue | US$11.24b |
| Gross Profit | US$50.13b |
| Other Expenses | US$39.68b |
| Earnings | US$10.45b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Oct 30, 2026
| Earnings per share (EPS) | 6.73 |
| Gross Margin | 81.69% |
| Net Profit Margin | 17.02% |
| Debt/Equity Ratio | 58.8% |
How did AZNS perform over the long term?
See historical performance and comparisonDividends
Does AZNS pay a reliable dividends?
See AZNS dividend history and benchmarks| AstraZeneca dividend dates | |
|---|---|
| Ex Dividend Date | Aug 06 2026 |
| Dividend Pay Date | Sep 08 2026 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 34 days |
Does AZNS pay a reliable dividends?
See AZNS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/04 10:02 |
| End of Day Share Price | 2026/08/04 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AstraZeneca PLC is covered by 56 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |